Dianthus Therapeutics, Inc. /DE/ 8-K

What Happened

• On March 26, 2026, Dianthus Therapeutics, Inc. announced via an SEC Form 8-K (Item 8.01) that it posted an updated corporate presentation on the investor relations section of its website. The presentation is filed as Exhibit 99.1 and is incorporated by reference into the 8-K. The filing was signed by Adam M. Veness, Esq., SVP, General Counsel and Secretary.

Key Details

• Filing date: March 26, 2026 (Form 8-K).
• Exhibit: 99.1 — Corporate Presentation of Dianthus Therapeutics, dated March 2026.
• The cover page interactive XBRL file (Exhibit 104) is included in the filing.
• The 8-K reports the posting of the presentation only; it does not announce earnings, executive changes, mergers, or other material events.

Why It Matters

• For investors, the updated corporate presentation is the company’s current public summary of strategy, pipeline, clinical status and corporate highlights — useful for reviewing the latest investor-facing information without waiting for a separate press release or earnings filing.
• Because this 8-K is informational (posting a presentation) and does not contain financial results or personnel changes, investors should treat it as a resource for company updates rather than a report of material corporate actions.